Metformin Use and the Outcome of Metastatic Renal Cell Carcinoma Treated with Sunitinib or Pazopanib

References

• Znaor A , Lortet-Tieulent J , Laversanne M , et al. International variations and trends in renal cell carcinoma incidence and mortality. Eur Urol . 2015;67(3):519. doi:10.1016/j.eururo.2014.10.002 25449206
   PubMed Web of Science ®Google Scholar
• Srigley JR , Delahunt B , Eble JN , et al. The International Society of Urological Pathology (ISUP) Vancouver classification of renal neoplasia. Am J Surg Pathol . 2013;37(10):1469–1489. doi:10.1097/PAS.0b013e318299f2d1 24025519
   PubMed Web of Science ®Google Scholar
• Motzer RJ , Hutson TE , Tomczak P , et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol . 2009;27(22):3584–3590. doi:10.1200/JCO.2008.20.1293 19487381
   PubMed Web of Science ®Google Scholar
• Sternberg CN , Davis ID , Mardiak J , et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized Phase III trial. J Clin Oncol . 2010;28(6):1061–1068. doi:10.1200/JCO.2009.23.9764 20100962
   PubMed Web of Science ®Google Scholar
• Nathan DM , Buse JB , Davidson MB , et al. Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia . 2009;52(1):17–30. doi:10.1007/s00125-008-1157-y 18941734
   PubMed Web of Science ®Google Scholar
• Cusi K , DeFronzo RA . Metformin: a review of its metabolic effects. Diabetes Rev . 1998;6(2):89–131.
   Google Scholar
• Samuel SM , Varghese E , Kubatka P , et al. Metformin: the answer to cancer in a flower? Current knowledge and future prospects of metformin as an anti-cancer agent in breast cancer. Biomolecules . 2019;9(12):846. doi:10.3390/biom9120846
   PubMed Web of Science ®Google Scholar
• Chen YC , Li H , Wang J . Mechanisms of metformin inhibiting cancer invasion and migration. Am J Transl Res . 2020;12(9):4885–4901.33042396
   PubMed Web of Science ®Google Scholar
• Chlebowski RT , McTiernan A , Aragaki AK , et al. Metformin and breast cancer incidence in postmenopausal diabetic women in the women’s health initiative (WHI). J Clin Oncol . 2011;29(11):3–1503. doi:10.1200/jco.2011.29.15_suppl.1503
   Web of Science ®Google Scholar
• Bansal M , Siegel E , Govindarajan R . The effect of metformin (M) on overall survival (OS) of patients (Pts) with colorectal cancer (CRC) treated with chemotherapy (CTX). J Clin Oncol . 2011;29(15):2608. doi:10.1200/jco.2011.29.15_suppl.2608
   Web of Science ®Google Scholar
• Mayer MJ , Klotz LH , Venkateswaran V . The effect of metformin use during docetaxel chemotherapy on prostate cancer-specific and overall survival of diabetic castration-resistant prostate cancer patients. J Urol . 2017;197(4):1068–1075. doi:10.1016/j.juro.2016.10.069 27984108
   PubMed Web of Science ®Google Scholar
• Lee CK , Jung M , Jung I , et al. Cumulative metformin use and its impact on survival in gastric cancer patients after gastrectomy. Ann Surg . 2016;263(1):96–102. doi:10.1097/SLA.0000000000001086 25575260
   PubMed Web of Science ®Google Scholar
• Lacroix O , Couttenier A , Vaes E , et al. Impact of metformin on gastric adenocarcinoma survival: a Belgian population based study. Cancer Epidemiol . 2018;53:149–155. doi:10.1016/j.canep.2018.02.001 29453032
   PubMed Web of Science ®Google Scholar
• Buchler T , Klapka R , Melichar B , et al. Sunitinib followed by sorafenib or vice versa for metastatic renal cell carcinoma – data from the Czech registry. Ann Oncol . 2012;23(2):395–401. doi:10.1093/annonc/mdr065 21536664
   PubMed Web of Science ®Google Scholar
• Therasse P , Arbuck SG , Eisenhauer EA , et al. New guidelines to evaluate the response to treatment in solid tumours. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst . 2000;92(3):205–216. doi:10.1093/jnci/92.3.205 10655437
   PubMed Web of Science ®Google Scholar
• Kahn BB , Alquier T , Carling D , et al. AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism. Cell Metab . 2005;1(1):15–25. doi:10.1016/j.cmet.2004.12.003 16054041
   PubMed Web of Science ®Google Scholar
• Sośnicki S , Kapral M , Węglarz L . Molecular targets of metformin antitumor action. Pharmacol Rep . 2016;68(5):918–925. doi:10.1016/j.pharep.2016.04.021 27362768
   PubMed Web of Science ®Google Scholar
• Woodard J , Joshi S , Viollet B , et al. AMPK as a therapeutic target in renal cell carcinoma. Cancer Biol Ther . 2010;10(11):1168–1177. doi:10.4161/cbt.10.11.13629 20948309
   PubMed Web of Science ®Google Scholar
• Decensi A , Puntoni M , Goodwin P , et al. Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis. Cancer Prev Res (Phila) . 2010;3(11):1451–1461. doi:10.1158/1940-6207.CAPR-10-0157 20947488
   PubMed Web of Science ®Google Scholar
• Gandini S , Puntoni M , Heckman-Stoddard BM , et al. Metformin and cancer risk and mortality: a systematic review and meta-analysis taking into account biases and confounders. Cancer Prev Res (Phila) . 2014;7(9):867–885. doi:10.1158/1940-6207.CAPR-13-0424 24985407
   PubMed Web of Science ®Google Scholar
• Li Y , Hu L , Xia Q , et al. The impact of metformin use on survival in kidney cancer patients with diabetes: a meta-analysis. Int Urol Nephrol . 2017;49(6):975–981. doi:10.1007/s11255-017-1548-4 28271326
   PubMed Web of Science ®Google Scholar
• Jiralerspong S , Palla SL , Giordano SH , et al. Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol . 2009;27(20):3297–3302. doi:10.1200/JCO.2009.19.6410 19487376
   PubMed Web of Science ®Google Scholar
• Lin JJ , Gallagher EJ , Sigel K , et al. Survival of patients with stage IV lung cancer with diabetes treated with metformin. Am J Respir Crit Care Med . 2015;191(4):448–454. doi:10.1164/rccm.201407-1395OC 25522257
   PubMed Web of Science ®Google Scholar
• Choi Y , Kim TY , Oh DY , et al. The impact of diabetes mellitus and metformin treatment on survival of patients with advanced pancreatic cancer undergoing chemotherapy. Cancer Res Treat . 2016;48(1):171–179. doi:10.4143/crt.2014.292 25779362
   PubMed Web of Science ®Google Scholar
• Psutka SP , Boorjian SA , Lohse CM , et al. The association between metformin use and oncologic outcomes among surgically treated diabetic patients with localized renal cell carcinoma. Urol Oncol . 2015;33(2):67 e15–23. doi:10.1016/j.urolonc.2014.07.008
   PubMed Web of Science ®Google Scholar
• Ersoy C , Kiyici S , Budak F , et al. The effect of metformin treatment on VEGF and PAI-1 levels in obese type 2 diabetic patients. Diabetes Res Clin Pract . 2008;81(1):56–60. doi:10.1016/j.diabres.2008.02.006 18358555
   PubMed Web of Science ®Google Scholar
• Lund SS , Tarnow L , Stehouwer CD , et al. Impact of metformin versus repaglinide on non-glycaemic cardiovascular risk markers related to inflammation and endothelial dysfunction in non-obese patients with type 2 diabetes. Eur J Endocrinol . 2008;158(5):631–641. doi:10.1530/EJE-07-0815 18426821
   PubMed Web of Science ®Google Scholar
• Hirsch HA , Iliopoulos D , Struhl K . Metformin inhibits the inflammatory response associated with cellular transformation and cancer stem cell growth. Proc Natl Acad Sci USA . 2013;110(3):972–977. doi:10.1073/pnas.1221055110 23277563
   PubMed Web of Science ®Google Scholar
• Esfahanian N , Shakiba Y , Nikbin B , et al. Effect of metformin on the proliferation, migration, and MMP-2 and −9 expression of human umbilical vein endothelial cells. Mol Med Rep . 2012;5(4):1068–1074. doi:10.3892/mmr.2012.753 22246099
   PubMed Web of Science ®Google Scholar
• Hakimi AA , Chen L , Kim PH , et al. The impact of metformin use on recurrence and cancer-specific survival in clinically localized high-risk renal cell carcinoma. Can Urol Assoc J . 2013;7(11–12):E687–91. doi:10.5489/cuaj.1447 24282458
   PubMed Web of Science ®Google Scholar
• Nayan M , Juurlink DN , Austin PC , et al. Canadian Drug Safety and Effectiveness Research Network (CDSERN). Medication use and kidney cancer survival: a population-based study. Int J Cancer . 2018;142(9):1776–1785. doi:10.1002/ijc.31204 29226327
   PubMed Web of Science ®Google Scholar
• Cheng JJ , Li H , Tan HS , et al. Metformin use in relation with survival outcomes of patients with renal cell carcinoma. Clin Genitourin Cancer . 2016;14(2):168–175. doi:10.1016/j.clgc.2015.12.012 26794391
   PubMed Web of Science ®Google Scholar
• Keizman D , Ish-Shalom M , Sella A , et al. Metformin use and outcome of sunitinib treatment in patients with diabetes and metastatic renal cell carcinoma. Clin Genitourin Cancer . 2016;14(5):420–425. doi:10.1016/j.clgc.2016.04.012 27211307
   PubMed Web of Science ®Google Scholar
• Hamieh L , McKay RR , Lin X , et al. Effect of metformin use on survival outcomes in patients with metastatic renal cell carcinoma. Clin Genitourin Cancer . 2017;15(2):221–229. doi:10.1016/j.clgc.2016.06.017 27460432
   PubMed Web of Science ®Google Scholar
• Pasha M , Sivaraman SK , Frantz R , et al. Metformin induces different responses in clear cell renal cell carcinoma caki cell lines. Biomolecules . 2019;9(3):113. doi:10.3390/biom9030113
   PubMed Web of Science ®Google Scholar
• Chrom P , Stec R , Semeniuk-Wojtas A , et al. Fuhrman grade and neutrophil-to-lymphocyte ratio influence on survival in patients with metastatic renal cell carcinoma treated with first-line tyrosine kinase inhibitors. Clin Genitourin Cancer . 2016;14(5):457–464. doi:10.1016/j.clgc.2016.02.005 26980234
   PubMed Web of Science ®Google Scholar